Sulphonylurea failure in type 2 diabetes: treatment with a basal insulin supplement.

Sulphonylurea failure in type 2 diabetes: treatment with a basal insulin supplement.

Many diabetic patients continue to have hyperglycaemia on maximal sulphonylurea therapy. Five different therapeutic options, with the prime aim of achieving normal fasting plasma glucose concentrations, have been compared in 15 asymptomatic, sulphonylurea-treated type 2 diabetic patients in a random...

Volledige beschrijving

Bibliografische gegevens
Hoofdauteurs:	Holman, R, Steemson, J, Turner, R
Formaat:	Journal article
Taal:	English
Gepubliceerd in:	1987

Gelijkaardige items

TWICE-DAILY SUBCUTANEOUS HUMAN PROINSULIN PROVIDES A SATISFACTORY BASAL INSULIN SUPPLEMENT IN TYPE-2 (NON-INSULIN-DEPENDENT) DIABETIC-PATIENTS
door: Holman, R, et al.
Gepubliceerd in: (1987)

Post-prandial amylin concentrations are increased by sulphonylurea, but unchanged by basal insulin, in NIDDM
door: Rachman, J, et al.
Gepubliceerd in: (1996)

UKPDS 26: Sulphonylurea failure in non-insulin-dependent diabetic patients over six years
door: Matthews, DR, et al.
Gepubliceerd in: (1998)

UKPDS 18: Estimated dietary intake in type 2 diabetic patients randomly allocated to diet, sulphonylurea or insulin therapy
door: Eeley, E, et al.
Gepubliceerd in: (1996)

COMPARISON OF TREATMENT OF MILD DIABETES WITH A BASAL INSULIN SUPPLEMENT OR SULFONYLUREA
door: Holman, R, et al.
Gepubliceerd in: (1977)

Post-prandial glycaemic reduction by an alpha-glucosidase inhibitor in type 2 diabetic patients with therapeutically attained basal normoglycaemia.
door: Holman, R, et al.
Gepubliceerd in: (1991)

Efficacy over six years of sulphonylurea plus insulin therapy in type 2 diabetic patients in the UKPDS
door: Cull, C, et al.
Gepubliceerd in: (2000)

UKPDS 26: Sulphonylurea failure in non-insulin-dependent diabetic patients over six years. UK Prospective Diabetes Study (UKPDS) Group.
door: Matthews, DR, et al.
Gepubliceerd in: (1998)

NASAL INSULIN OUTPATIENT STUDY IN TYPE-I DIABETES
door: Holman, R, et al.
Gepubliceerd in: (1992)

UKPDS 18: estimated dietary intake in type 2 diabetic patients randomly allocated to diet, sulphonylurea or insulin therapy. UK Prospective Diabetes Study Group.
door: Eeley, E, et al.
Gepubliceerd in: (1996)

This house believes that sulphonylureas should not be used routinely as second-line treatments for patients with type 2 diabetes
door: Ryder, R, et al.
Gepubliceerd in: (2016)

Sulphonylureas in the management of type 2 diabetes: To be or not to be?
door: André J. Scheen
Gepubliceerd in: (2021-01-01)

Beta-cell function improved by supplementing basal insulin secretion in mild diabetes.
door: Turner, R, et al.
Gepubliceerd in: (1976)

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)
door: Turner, R, et al.
Gepubliceerd in: (1998)

TIMING OF NASAL INSULIN DELIVERY IN TYPE-I DIABETES
door: Holman, R, et al.
Gepubliceerd in: (1993)

Permanent neonatal diabetes: combining sulphonylureas with insulin may be an effective treatment
door: Misra, S, et al.
Gepubliceerd in: (2018)

Maintenance of basal plasma glucose and insulin concentrations in maturity-onset diabetes.
door: Holman, R, et al.
Gepubliceerd in: (1979)

Differences in insulin treatment satisfaction following randomized addition of biphasic, prandial or basal insulin to oral therapy in type 2 diabetes.
door: Farmer, A, et al.
Gepubliceerd in: (2011)

LACK OF BENEFIT FROM GUAR ADMINISTRATION IN WELL CONTROLLED NON-INSULIN-DEPENDENT DIABETIC-PATIENTS
door: Holman, R, et al.
Gepubliceerd in: (1984)

Sulphonylurea therapy over six years does not delay progression to diabetes
door: Herlihy, O, et al.
Gepubliceerd in: (2000)

HUMAN ULTRALENTE INSULIN
door: Holman, R, et al.
Gepubliceerd in: (1983)

Intermediate acting insulin for type 2 diabetes.
door: Turner, R, et al.
Gepubliceerd in: (1985)

Factors influencing utilization of different types of sulphonylureas amongst type 2 diabetes patients
door: Huri, H.Z., et al.
Gepubliceerd in: (2010)

Induced basal normoglycemia and altered platelet aggregation in non-insulin-dependent diabetes.
door: Evans, R, et al.
Gepubliceerd in: (1982)

Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes.
door: Holman, R, et al.
Gepubliceerd in: (2007)

Sulphonylureas and hypoglycaemia.
door: Ferner, R, et al.
Gepubliceerd in: (1988)

A practical guide to basal and prandial insulin therapy.
door: Holman, R, et al.
Gepubliceerd in: (1985)

Human ultralente insulin.
door: Holman, R, et al.
Gepubliceerd in: (1984)

Insulin deficiency and insulin resistance interaction in diabetes: estimation of their relative contribution by feedback analysis from basal plasma insulin and glucose concentrations.
door: Turner, R, et al.
Gepubliceerd in: (1979)

Insulin therapy in type II diabetes.
door: Holman, R, et al.
Gepubliceerd in: (1995)

UKPDS - 6-YEAR TRIAL OF SULFONYLUREA, INSULIN AND METFORMIN THERAPY IN TYPE-2 DIABETIC-PATIENTS WITH DIET FAILURE
door: Cull, C, et al.
Gepubliceerd in: (1995)

Identification of First Case of Neonatal Diabetes in Singapore and Successful Conversion from Insulin to Sulphonylurea
door: Rashida Vasanwala MD (Paeds), MRCPCH (UK), et al.
Gepubliceerd in: (2010-06-01)

Indirect comparison of lixisenatide versus neutral protamine Hagedorn insulin as add-on to metformin and sulphonylurea in patients with type 2 diabetes mellitus
door: Fournier, Marie, et al.
Gepubliceerd in: (2014-10-01)

Diabetes: The quest for basal normoglycaemia.
door: Holman, R, et al.
Gepubliceerd in: (1977)

2-YEAR PROSPECTIVE-STUDY OF IMPROVED DIABETIC CONTROL IN INSULIN-DEPENDENT DIABETIC-PATIENTS WITH BACKGROUND RETINOPATHY
door: Holman, R, et al.
Gepubliceerd in: (1982)

Rapid restoration of normoglycaemia using intravenous insulin boluses.
door: Dunnett, J, et al.
Gepubliceerd in: (1990)

Basal insulin therapy in type 2 diabetes.
door: Bethel, M, et al.
Gepubliceerd in: (2005)

Combination of basal insulin and GLP-1 receptor agonist: is this the end of basal insulin alone in the treatment of type 2 diabetes?
door: Rodrigo Oliveira Moreira, et al.
Gepubliceerd in: (2018-04-01)

Efficacy and safety of insulin lispro protamine suspension as basal supplementation in patients with type 2 diabetes
door: Dario Giugliano, et al.
Gepubliceerd in: (2012-06-01)

Pharmacogenetics in Type 2 diabetes: variation in TCF7L2 influences response to sulphonylureas
door: Pearson, E, et al.
Gepubliceerd in: (2007)